Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses
W J Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Fengwei Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Xinjie Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Kang Shao(Chinese Academy of Medical Sciences & Peking Union Medical College), Feiyue Feng(Chinese Academy of Medical Sciences & Peking Union Medical College), Yousheng Mao(Chinese Academy of Medical Sciences & Peking Union Medical College), Qianqian Sun(Jiangsu Hengrui Medicine (China)), Xiuli Tao(Chinese Academy of Medical Sciences & Peking Union Medical College), Y S Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Wendong Lei(Chinese Academy of Medical Sciences & Peking Union Medical College), B. Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Kai Su(Chinese Academy of Medical Sciences & Peking Union Medical College), Shuhang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qi Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Dali Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianming Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhishan Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Liang Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Lin Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Ning Wu(Chinese Academy of Medical Sciences & Peking Union Medical College), Ning Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Jun Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Fang Lv(Liaoning Normal University), Xiaowei Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Liangze Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 2
Related Papers
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128
CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells
|Journal of Experimental & Clinical Cancer Research|2022|115